Hypnion Announces Positive And Robust Phase II Results For Novel Sleep Drug - HY10275
Sun, 07 Jan 2007 08:00 AM EST
... Hypnion, Inc. today announced that it met the primary and secondary endpoints in the company's initial Phase II clinical trial evaluating HY10275 at doses of 1 mg and 3 mg in adults with transient insomnia. HY10275 is a proprietary compound discovered and developed by Hypnion as a dual-acting H1 / 5HT2a compound using the SCORE-2004(TM) technology. [click link for full article] ...
Related Topics
- Sleep Disorders
- Sleep Apnea
- Apnea
- Clinical Trials
- Drug Safety
- Prescription Drugs
- Urinalysis
- Doxylamine
- Nystatin and Triamcinolone
- Drug Side Effects
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Drug Abuse
- Drug Information
- Tb
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Myoclonus
- Kniest dysplasia
- Insomnia

Not Signed In -


